翰宇药业 reported revenue of ¥0.69B for the period ended 2026-06-30, +25.3% year on year. Net income was ¥0.24B, a 34.2% net margin on a 62.9% gross margin. The largest revenue line is 原料药 at 79% of the total. Free cash flow for the period was ¥0.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.69B | +25.3% |
| Gross profit | ¥0.43B | — |
| Operating income | ¥0.25B | — |
| Net income | ¥0.24B | +63.1% |
| Gross margin | 62.9% | Net margin 34.2% |
| Revenue Q/Q | +30.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 原料药 | ¥0.55B | 79.4% |
| 制剂 | ¥0.06B | 9.4% |
| 客户肽 | ¥0.04B | 5.8% |
| 其他业务收入 | ¥0.02B | 3.5% |
| 固体类 | ¥0.01B | 1.8% |
| 大消费品及其他 | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.26B | 37.1% |
| R&D | ¥0.10B | 14.3% |
| SG&A | ¥0.09B | 12.7% |
| Tax & other | ¥0.02B | 2.5% |
| Item | Amount |
|---|---|
| Total assets | ¥3.55B |
| Total liabilities | ¥2.69B |
| Shareholders' equity | ¥0.87B |
| Equity / assets | 24.4% |
| Operating cash flow | ¥0.24B |
| Capital expenditure | ¥0.13B |
| Free cash flow | ¥0.11B |
| Cash conversion (OCF / net income) | 130% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
高盟新材 ・ 海伦哲 ・ 聚光科技 ・ 舒泰神 ・ *ST天喻 ・ 理邦仪器 ・ 欣旺达 ・ 行云科技 ・ 森远股份 ・ *ST亿通 ・ *ST易录 ・ 佳讯飞鸿
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies